LAWSUITS FILED AGAINST TAL, ASTR and AKBA - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / March 30, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Tal Education Group TAL
CONTACT JAKUBOWITZ ABOUT TAL:
https://claimyourloss.com/securities/tal-education-group-loss-submission-form/?id=25359&from=1
Class Period: April 26, 2018 - July 22, 2021
Lead Plaintiff Deadline : April 5, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) TAL's revenue and operational growth was the result of deceptive marketing tactics and illicit business practices that flouted Chinese laws, regulations and policies, and exposed the Company to an extreme risk that more draconian measures would be imposed on the Company; (b) TAL had engaged in misleading and fraudulent advertising practices, including the provision of false and misleading discount information designed to obfuscate the true cost of the Company's programs to its customers, the creation of fake customer reviews designed to fraudulently lure new customers to TAL programs, the misrepresentation of teacher qualifications and course qualities, and the marketing of rigged promotional events; (c) TAL had defied Chinese policies designed to alleviate the burden imposed by tutoring services on students and their families, including by imposing hefty advances and recurring debt payments on course enrollees, by offering courses designed to give affluent students unfair advantages, by holding courses outside of allowable tutoring hours, and by linking for-profit courses to government-mandated schooling; (d) as a result of the foregoing, TAL was subject to an extreme undisclosed risk of adverse enforcement actions, regulatory fines and penalties, and the imposition of new rules and regulations adverse to the Company's business and financial interests; and (e) as a result of the foregoing, TAL's historical growth was not sustainable or the result of legitimate business tactics as represented, and defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and lacked a reasonable factual basis.

Astra Space Inc. f/k/a Holicity Inc. ASTR
CONTACT JAKUBOWITZ ABOUT ASTR:
https://claimyourloss.com/securities/astra-space-inc-f-k-a-holicity-inc-loss-submission-form/?id=25359&from=1
Class Period: February 2, 2021 - December 29, 2021
Lead Plaintiff Deadline: April 11, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Astra cannot launch "anywhere"; (2) Astra significantly overstated its addressable market; (3) Astra overstated the effectiveness of its designs and reliability; (4) Astra significantly overstated its plans for diversification and its broadband constellation plan; and (5) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Akebia Therapeutics, Inc. AKBA
CONTACT JAKUBOWITZ ABOUT AKBA:
https://claimyourloss.com/securities/akebia-therapeutics-inc-loss-submission-form/?id=25359&from=1
Class Period: June 28, 2018 - September 2, 2020
Lead Plaintiff Deadline: May 13, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat's overall commercial and regulatory prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law